Publications by authors named "Ran Reshef"

Claim this Profile
A
A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma.
Rodney Macedo, David W Harle, Kevin Hoffer-Hawlik, Ximi K Wang, Thomas McMahon-Skates, Ran Reshef

bioRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.
Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis E Louloudis, Paibel Aguayo-Hiraldo, Ran Reshef

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L Ulrickson, Ran Reshef

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.
Evelyn H Orlando, Patrick Gould, Brian Cuzzo, Maegan Ford, Yuxuan Chen, Ran Reshef

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Binod Dhakal, Othman S Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Ran Reshef

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Yannis K Valtis, Chenyu Lin, David Nemirovsky, Sean M Devlin, Kai Rejeski, Ran Reshef

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies.
Alexander J Jonokuchi, Amy W Yu, Gurcharanjeet Kaur, Prakash Satwani, Ran Reshef

J Child Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electroencephalography in patients with immune effector cell-associated neurotoxicity syndrome (ICANS).
Sarah Flanagan Wesley, Alec R Friedman, Christian Gordillo, Paul F Kent, Ran Reshef

J Neurol Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.
Ioannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos, Ran Reshef

Transplant Cell Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life-Threatening Cytopenias in a Jehovah's Witness Following CD19-Directed Chimeric Antigen Receptor T Cell Therapy.
Corinne J Shamehdi, Christian A Gordillo, Ahmed Sawas, Rodney Macedo, Markus Y Mapara, Ran Reshef

EJHaem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.
Matthew J Frigault, Richard T Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah, Ran Reshef

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous T cell therapy for PRAME advanced solid tumors in HLA-A*02 patients: a phase 1 trial.
Martin Wermke, Dejka M Araujo, Manik Chatterjee, Apostolia M Tsimberidou, Tobias A W Holderried, Ran Reshef

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Autologous T cell therapy for PRAME advanced solid tumors in HLA-A*02 patients: a phase 1 trial.
Martin Wermke, Dejka M Araujo, Manik Chatterjee, Apostolia M Tsimberidou, Tobias A W Holderried, Ran Reshef

Nat Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.
Sameem Abedin, Michael J Martens, Javier Bolaños-Meade, Monzr M Al Malki, Qinghua Lian, Ran Reshef

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma.
Aliya Masihuddin, Jason Liebowitz, Ran Reshef, Joan Bathon

Rheumatology (Oxford)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Ran Reshef

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR T-cell therapy chest CT manifestations.
Dorine de Jong, Saheeb Ahmed, Belinda Dsouza, Mary Salvatore, Benjamin May, Ran Reshef

Clin Imaging· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Ran Reshef

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatiotemporal Single-Cell Analysis Reveals T Cell Clonal Dynamics and Phenotypic Plasticity in Human Graft-versus-Host Disease.
Lingting Shi, Ajna Uzuni, Ximi K Wang, Michael Pressler, David W Harle, Ran Reshef

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, Ran Reshef

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report.
Tyler Ruemmele, Rodney Macedo, Mark N Stein, Hei Ton Chan, Markus Y Mapara, Ran Reshef

Front Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko, Ran Reshef

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk, Ran Reshef

Transplant Cell Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Risk Factors for Predicting Immune Effector Cell-Associated Neurotoxicity Syndrome.
Alec R Friedman, Ceren Tozlu, Christian A Gordillo, Hei Ton Chan, Ran Reshef

medRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial.
Mark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, Usama S Gergis, Martin E Guiterrez, Ran Reshef

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis